Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Barbour, T; Scully, M; Ariceta, G; Cataland, S; Garlo, K; Heyne, N; Luque, Y; Menne, J; Miyakawa, Y; Yoon, SS; Kavanagh, D; Babu, S; Broeders, N; Lietar, N; Brown, F; Campbell, P; Campistol, JM; Chowdhury, P; Kasimatis, T; Cirami, L; Caroti, L; Antognoli, G; Delmas, Y; Dobronravov, V; Gaeckler, A; Garrouste, C; Greenwood, G; Griffin, S; Huang, CC; Chen, IR; Huang, S; Kim, JS; La Manna, G; Le Quintrec, M; Jeantet, G; Fumie, I; Rondeau, E; Haller, H; Morelle, J; Goffin, E; Muhlfeld, A; Nagaraj, S; Arepally, G; Oh, D; Okumi, M; Terente, MP; Provot, F; Schönermarck, U; Fischereder, M; Terrada, NR; Seitz-Polski, B; Favre, G; Boyer-Suavet, S; Vinogradova, M; Kirsanova, T; Wong, EKS

File(s) under permanent embargo

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Version 3 2024-06-19, 12:08

Version 2 2024-06-13, 17:15

Version 1 2022-10-25, 22:31

journal contribution

posted on 2024-06-19, 12:08 authored by T Barbour, M Scully, G Ariceta, S Cataland, K Garlo, N Heyne, Y Luque, J Menne, Y Miyakawa, SS Yoon, D Kavanagh, S Babu, N Broeders, N Lietar, F Brown, P Campbell, JM Campistol, P Chowdhury, T Kasimatis, L Cirami, L Caroti, G Antognoli, Y Delmas, V Dobronravov, A Gaeckler, C Garrouste, G Greenwood, S Griffin, CC Huang, IR Chen, S Huang, JS Kim, G La Manna, M Le Quintrec, G Jeantet, I Fumie, E Rondeau, H Haller, J Morelle, E Goffin, A Muhlfeld, S Nagaraj, G Arepally, D Oh, M Okumi, MP Terente, F Provot, U Schönermarck, M Fischereder, NR Terrada, B Seitz-Polski, G Favre, S Boyer-Suavet, M Vinogradova, T Kirsanova, EKS Wong

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

History

Journal

Kidney international reports

Volume

6

Pagination

1603-1613

Location

Amsterdam, The Netherlands

Publisher DOI

https://doi.org/10.1016/j.ekir.2021.03.884

ISSN

2468-0249

eISSN

2468-0249

Language

eng

Publication classification

C1 Refereed article in a scholarly journal

Issue

6

Publisher

Elsevier

Usage metrics

Keywords

atypical hemolytic uremic syndrome complement hemolytic uremic syndrome kidney failure ravulizumab thrombotic microangiopathy

Licence

CC BY-NC-ND 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

File(s) under permanent embargo

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

History

Journal

Volume

Pagination

Location

Publisher DOI

ISSN

eISSN

Language

Publication classification

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports